NASDAQ: DYN

Dyne Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for DYN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Dyne Therapeutics, Inc. (NASDAQ: DYN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 05:59 UTC.

What Dyne Therapeutics, Inc. does

The company is a clinical-stage biopharmaceutical firm developing treatments for genetically driven neuromuscular diseases using its proprietary FORCE platform. The FORCE platform combines a transferrin receptor 1-targeting antibody fragment with various therapeutic payloads—such as oligonucleotides and enzymes—designed to deliver treatments to muscle tissue and the central nervous system.

Summarized from Dyne Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for DYN are available in Oxford Ledge.
Open DYN in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-06

2026-10-06DirectorPurchase2,500$40.0K
2026-09-08Chief Commercial OfficerSale-900$21.9K
2026-09-08Chief Commercial OfficerSale-185$3.5K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

BlackRock, Inc.12,404,330$275.50M+6.0%
Jupiter Topco LLC11,997,738$266.63MNEW
FMR LLC11,207,000$248.91M+25.8%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-03-20Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-03-25Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-05-25Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersLawrence KleinEstimatedSEC 8-K →

Company news

View all →

Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says
Yahoo2026-09-09
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
SeekingAlpha2026-09-09
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
globenewswire.com2026-09-08
Dyne Therapeutics: A Buy, With Caveats, On DMD Progress
Seeking Alpha Feed2026-07-20
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
fool.com2026-07-04

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DYN and 5,000+ tickers.

Create a free account — keep DYN

For your agent

GET /api/data?ticker=DYN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt